子宫内膜癌术后手术部位感染相关因素分析

Related factors for postoperative surgical site infections in patients with endometrial carcinoma

  • 摘要: 目的 分析子宫内膜癌患者术后手术部位感染的相关因素,为临床提供参考依据。方法 回顾2012年2月-2018年6月贵州医科大学第三附属医院手术治疗的587例子宫内膜癌患者临床资料,对其手术部位感染的相关因素进行单因素及多因素logistic回归分析。结果 587例子宫内膜癌手术患者,发生手术部位感染65例,感染率为11.07%。多因素logistic模型回归分析显示,手术方式-开腹(OR=2.167, 95%CI为1.099~4.271)、接受化疗(OR=3.495, 95%CI为1.811~6.747)、血糖≥10mmol/L(OR=6.324, 95%CI为2.478~16.140)、FIGO分期-ⅢⅣ(OR=2.050, 95%CI为1.131~3.715)、引流管放置时间≥7d(OR=2.640, 95%CI为1.404~4.964)均是子宫内膜癌手术部位感染的独立相关因素(P<0.05)。结论 手术治疗子宫内膜癌时,术前应有效控制血糖,尽量采取微创手术治疗,术后及时评估引流与拨管,缩短不必要引流时间,制定合理化疗方案。

     

    Abstract: OBJECTIVE To investigate the related factors for postoperative surgical site infections in patients with endometrial carcinoma so as to provide guidance for clinical treatment. METHODS The clinical data of 587 patients with endometrial carcinoma who received surgical procedures in Third Affiliated Hospital of Guizhou Medical University from Feb 2012 to Jun 2018 were retrospectively analyzed, and the univariate analysis and multivariate logistic regression analysis were performed for the related factors for the surgical site infections. RESULTS Of the 587 patients with endometrial carcinoma, 65 had surgical site infections, with the infection rate 11.07%.The multivariate logistic regression analysis indicated that the laparoscopy (OR=2.167, 95%CI:1.099~4.271), chemotherapy (OR=3.495, 95%CI:1.811~6.747 ), blood glucose no less than 10mmol/L(OR=6.324, 95%CI:2.478~16.140), FIGO stage-ⅢⅣ(OR=2.050, 95%CI:1.131~3.715) and time of drainage tube indwelling no less than 7 days (OR=2.640, 95%CI:1.404~4.964)were the independent influencing factors for the surgical site infections in the patients with endometrial carcinoma (P<0.05). CONCLUSION It is necessary to effectively control the blood glucose for the patients with endometrial carcinoma who intend to receive surgical procedures, try to carry out minimally invasive surgery, evaluate the drainage and removal of tubes, shorten the draining indwelling time and put forward reasonable chemotherapy program.

     

/

返回文章
返回